NCT00551291View on ClinicalTrials.gov

A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes.

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

June 30, 2009

Study Completion Date

June 30, 2009

Conditions
Myelodysplastic Syndromes
Interventions
DRUG

Mycophenolate mofetil

1 gm twice daily orally until end of study.

DRUG

Prednisone

10 mg/day orally until end of study.

DRUG

Erythropoietin Beta

Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.

Trial Locations (8)

11009

Cadiz

28040

Madrid

48903

Barakaldo

08003

Barcelona

08025

Barcelona

08035

Barcelona

08036

Barcelona

07198

Palma de Mallorca

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT00551291 - A Study of NeoRecormon (Epoetin Beta), CellCept (Mycophenolate Mofetil) and Prednisone in Patients With Low or Intermediate Myelodysplastic Syndromes. | Biotech Hunter | Biotech Hunter